Abstract 144P
Background
This study was conducted to evaluate the relation of DNA damage repair (DDR) to clinical outcomes in gastric cancer patients with stage II or III treated gastrectomy.
Methods
From January 2005 to December 2017, 217 patients with stage II or III gastric cancer were analyzed for disease free survival (DFS) and overall survival according to DDR gene status. Immunohistochemical assessment of MLH1, MSH2, ARID1A, PARP-1, BRCA1 and ATM was performed in biologic samples.
Results
Among the 217 patients, the most commonly mutated DDR gene was MSH2 (n = 208, 95.9%), followed by BRCA1 (n = 191, 88.0%), MLH1 (n = 184, 84.8%), ARID1A (n = 170, 78.3%), ATM (n = 146, 67.3%) and PARP-1 (n=120, 55.3%). The high expression levels of PARP-1 group had a significantly longer 5-year OS rate as compared to low expression level of PARP-1 group (62.7% vs. 48.1%, HR 0.649, 95% CI 0.433-0.974, P = 0.035). In the multivariate OS analysis, TNM stage (HR = 5.202, P < 0.001), high expression PARP-1 (HR = 0.583, P = 0.011) and adjuvant chemotherapy (HR = 0.382, P <0.001) were only significantly prognostic factor.
Conclusions
A subgroup of patients with gastric cancer may benefit from targeted therapy. High PARP-1 expression may be a good prognostic factor for gastric cancer particularly, stage II or III gastric cancer post-surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session
193P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
Presenter: Andrew Dean
Session: e-Poster Display Session